On April 7, 2025 Genoscience Pharma reported that it has granted Genfit exclusive rights to develop and commercialize GNS561 for oncology indications (Press release, GenoScience, APR 7, 2025, View Source [SID1234651816]). This strategic agreement marks a significant step in advancing GNS561’s clinical potential in cancer treatment. Genfit will lead the development efforts, leveraging its strong expertise and infrastructure in oncology drug development. In return, Genoscience Pharma secures a potential return on investment through upfront payments, milestone-based compensations, and royalties on future sales. The agreement is designed to maximize the value of GNS561 while ensuring its accelerated path to market. GNS561 has shown promise in preclinical and early clinical studies, particularly in hard-to-treat cancers. This partnership allows both companies to focus on their core strengths while sharing the value creation. Genoscience Pharma retains a financial stake in GNS561’s success without bearing the full burden of clinical and commercial development. The deal reflects a shared commitment to innovation and patient impact. It also strengthens Genfit’s pipeline with a differentiated oncology asset.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!